Close Menu
Home › BARDA Awards DxTerity Diagnostics $150M Contract for Radiation Exposure Test

BARDA Awards DxTerity Diagnostics $150M Contract for Radiation Exposure Test

Oct 05, 2016

NEW YORK (GenomeWeb) — The US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) has awarded a contract worth up to $150 million to DxTerity Diagnostics to develop and deliver its REDI-Dx biodosimetry test for radiation exposure, the firm announced today.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

May
08
Featured Webinar

OncoBEAM ctDNA Testing for Early Response Prediction and Therapy Surveillance in Melanoma and Pancreatic Cancer

Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

May
22
Featured Webinar

A Digital PCR Liquid Biopsy Workflow for Mutation Detection and Therapeutic Monitoring

This webinar will outline the entire liquid biopsy workflow from cell-free DNA isolation to mutation detection by Crystal Digital PCR with the Naica System from Stilla Technologies.

What's Popular?

In PCR

  1. American Cancer Society Philanthropic Fund BrightEdge Invests in Castle Bio

  2. Progenity Launches Prenatal Monogenic Disease Screen, Develops New Test Technologies

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.